Live
BioPharma DiveSummit pulls $500M share sale a day after announcing itEndpoints NewsDrugmakers are turning to logistics providers as trade disruptions linger, DHL exec saysBioPharma DiveSensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyEndpoints NewsSummit withdraws $500M offering, citing 'market conditions'Clinical OMICsLipid-Protein Biomarker Makes Clinical Debut with Early Ovarian Cancer DetectionEndpoints NewsSensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophyEndpoints NewsCamurus’ second CRL for acromegaly drug; Teva details workforce cutsFierceBiotechFierce Biotech heading to UK to host event amid London Life Sciences WeekEndpoints NewsBiopharma pay report: Top-paid CSOs, CMOs of 2025Endpoints NewsKardigan plans $320M IPO for heart drugs as Nasdaq listings gain steamPharmaVoiceCompetition is brewing between ADCs and bispecificsBioWorldInnovo Therapeutics synthesizes new NMT1 inhibitors
Endpoints News 26 nov. 2025

Kallyope scraps one of two mid-stage migraine drugs

Kallyope scraps one of two mid-stage migraine drugs

Original
Contenu indisponible. Consultez la source originale.